GSK’s Requip CR Tablets More Economical and Effective; Sales May Decrease despite Investment in Improved Formulation

Nobutaka Hattori, Professor, Department of Neurology, Juntendo University School of Medicine GlaxoSmithKline K.K. (GSK) launched the controlled-release Parkinson’s disease treatment Requip CR Tablets (ropinirole HCl) on August 28. The Health Insurance Bureau’s Medical Economics Division issued an advisory notification on...read more